Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
In a possible redemption for the TREM2 space in Alzheimer’s disease, Vigil Neuroscience announced positive early-stage data Thursday for its...
promise
Pomalidomide shows promise in enhancing immune responses in myeloma
A new editorial was published in Oncoscience's Volume 12 on January 14, 2025, titled "Pomalidomide improved immune profiles in myeloma."...
:max_bytes(150000):strip_icc()/4000x1332_HLT_Primary_V2-22628e3c47ed47d3a5247039f6b7c9b1.jpg "Best, Tested Sleep Products of 2025")
.jpg "The Best Zinc-Rich Foods to Support Your Immune System")